Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
The James Hutton Institute maintains 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This number 3 also characterizes the distinct examiners and distinct art units, showing a total lack of overlap. Such a distribution suggests a diverse portfolio where each pending matter is being evaluated in a unique administrative and technical context. Practitioners should be prepared for varied examiner behavior across these different units.
CRAIGO, BAHAR ALAWI is the busiest examiner for the institute, currently handling 1 busiest examiner pending action. Because the total number of pending office actions is the previously stated 3, this examiner's workload represents a specific portion of the current prosecution activity. The presence of multiple examiners and units indicate that no single set of examination trends will apply to the whole portfolio. Success requires adapting to the specific standards of each distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580652 | BIODEGRADABLE AND REUSABLE CELLULOSIC MICROPOROUS SUPERABSORBENT MATERIALS | CRAIGO, BAHAR ALAWI | — |
| 18564149 | FLEXIBLE EXPRESSION VECTOR SYSTEMS AND APPLICATION OF SAME TO VACCINES AND IMMUNOTHERAPEUTICS | MATALKAH, FATIMAH KHALAF | — |
| 18558241 | SARS-COV-2 MULTI-EPITOPE VACCINES | ZOU, NIANXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580652 | BIODEGRADABLE AND REUSABLE CELLULOSIC MICROPOROUS SUPERABSORBENT MATERIALS | CRAIGO, BAHAR ALAWI | — |
| 18564149 | FLEXIBLE EXPRESSION VECTOR SYSTEMS AND APPLICATION OF SAME TO VACCINES AND IMMUNOTHERAPEUTICS | MATALKAH, FATIMAH KHALAF | — |
| 18558241 | SARS-COV-2 MULTI-EPITOPE VACCINES | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1638 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580652 | BIODEGRADABLE AND REUSABLE CELLULOSIC MICROPOROUS SUPERABSORBENT MATERIALS | CRAIGO, BAHAR ALAWI | 1699 | §102§103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18564149 | FLEXIBLE EXPRESSION VECTOR SYSTEMS AND APPLICATION OF SAME TO VACCINES AND IMMUNOTHERAPEUTICS | MATALKAH, FATIMAH KHALAF | 1638 | §102§103§112 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18558241 | SARS-COV-2 MULTI-EPITOPE VACCINES | ZOU, NIANXIANG | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe James Hutton Institute has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Bahar Alawi Craigo has the most, with 1 of The James Hutton Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
